{"id":22783,"date":"2023-05-19T15:05:38","date_gmt":"2023-05-19T09:35:38","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=22783"},"modified":"2023-05-24T09:32:11","modified_gmt":"2023-05-24T04:02:11","slug":"graves-ophthalmopathy-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment","title":{"rendered":"Graves\u2019 Ophthalmopathy Treatment Market: A Billion-Dollar Opportunity For Pharma Companies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0354942ebd7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0354942ebd7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\/#Current_Pharmacological_Options_for_Graves_Ophthalmopathy_Treatment\" >Current Pharmacological Options for Graves\u2019 Ophthalmopathy Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\/#TEPEZZA_One_of_the_Most_Successful_Rare_Disease_Medicine_Launches_in_History\" >TEPEZZA: One of the Most Successful Rare Disease Medicine Launches in History<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\/#Key_Competitors_in_Pipeline_for_Graves_Ophthalmopathy_Treatment\" >Key Competitors in Pipeline for Graves\u2019 Ophthalmopathy Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\/#Future_Graves_Ophthalmopathy_Treatment_Looks_Promising\" >Future Graves\u2019 Ophthalmopathy Treatment Looks Promising&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p>Graves\u2019 ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most frequent extrathyroidal manifestation of Graves\u2019 disease. The majority of Graves\u2019 ophthalmopathy cases are caused due to Graves\u2019 disease, and only a small percentage of these patients arise from other euthyroid or hypothyroid disorders.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em><strong>As per DelveInsight\u2019s estimates, as of 2022, ~2.4 million people were living with Graves\u2019s ophthalmopathy across 7MM. The US contributed to the largest <\/strong><\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-epidemiology-forecast\"><strong><em>prevalent population of Graves\u2019 ophthalmopathy<\/em><\/strong><\/a><em><strong>, acquiring ~42% of the 7MM in 2022. Females constitute ~80% of the prevalent population. It tends to be more severe in men, in whom it occurs at an older age than in women. Moreover, 3% &#8211; 5% may develop sight-threatening diseases, such as compressive optic neuropathy or exposure keratopathy.<\/strong><\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The diagnosis and treatment rate of Graves\u2019 ophthalmopathy is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for Graves\u2019 ophthalmopathy treatment, thus leading to an increase in awareness among patients and clinicians.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/graves-ophthalmopathy-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-1024x194.png\" alt=\"Graves\u2019 Ophthalmopathy Infographics\" class=\"wp-image-22795\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19145648\/Graves-Ophthalmopathy-Infographics.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-pharmacological-options-for-graves-ophthalmopathy-treatment\"><span class=\"ez-toc-section\" id=\"Current_Pharmacological_Options_for_Graves_Ophthalmopathy_Treatment\"><\/span><strong>Current Pharmacological Options for Graves\u2019 Ophthalmopathy Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Current pharmacological management options for graves\u2019 ophthalmopathy treatment target only <strong>1\/10th<\/strong> of the diagnosed population. Graves\u2019 ophthalmopathy is managed using a combination of basic, medicinal, and surgical treatments, depending on the severity of the patient&#8217;s symptoms. The optimal Graves\u2019 ophthalmopathy treatment goal is to reduce the risk of visual difficulties, minimize adverse effects, eliminate the need for surgical treatments, restore thyroid function, and prevent Graves\u2019 ophthalmopathy from progressing or recurring.<\/p>\n\n\n\n<p>Graves\u2019 ophthalmopathy is often a single, self-limiting episode that can be separated into two phases based on the disease\u2019s inflammatory activity. The acute, inflammatory phase normally responds to immunosuppressive anti-inflammatory medication, depending on the degree of involvement. Artificial tear drops can aid with dry eye relief in people with mild Graves\u2019 ophthalmopathy. Supplementing with selenium can also be useful. If Graves\u2019 ophthalmopathy is acute, a small number of individuals with mild Graves\u2019 ophthalmopathy may be recommended for low-dose immunomodulation. It is critical to create an early immunosuppressive treatment that restricts the progression of the inflammatory illness in moderate-severe types. Thyroid disease management can enhance orbital involvement, while the course is largely independent in most individuals.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091942\/Current-Therapies-for-Graves-Ophthalmopathy.png\" alt=\"Current Therapies for Graves\u2019 Ophthalmopathy\" class=\"wp-image-22788\" width=\"554\" height=\"273\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091942\/Current-Therapies-for-Graves-Ophthalmopathy.png 739w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091942\/Current-Therapies-for-Graves-Ophthalmopathy-300x148.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091942\/Current-Therapies-for-Graves-Ophthalmopathy-150x74.png 150w\" sizes=\"(max-width: 554px) 100vw, 554px\" \/><\/figure>\n\n\n\n<p>The pharmaceutical medications used to manage Graves\u2019 ophthalmopathy are <strong>glucocorticoids, mycophenolate, rituximab, tocilizumab, teprotumumab, cyclosporine\/mTOR inhibitors<\/strong>, and various additional forms of Graves\u2019 ophthalmopathy treatment. Currently, <strong>teprotumumab <\/strong>is the only <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-market\">FDA-approved therapy for Graves\u2019 ophthalmopathy treatment<\/a>; for this reason, research into new drugs is unsurprisingly demanding.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TEPEZZA_One_of_the_Most_Successful_Rare_Disease_Medicine_Launches_in_History\"><\/span><strong>TEPEZZA: One of the Most Successful Rare Disease Medicine Launches in History<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>TEPEZZA (teprotumumab)<\/strong> developed by <strong>Horizon Therapeutics<\/strong> is the only FDA-approved Graves\u2019 ophthalmopathy treatment. TEPEZZA became the blockbuster therapy within two years of launch. Following a 24-week course of therapy, significant improvements in proptosis, diplopia, and quality of life have been observed. Teprotumumab is a completely human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor; its metabolism has not been thoroughly characterized. However, it is expected to be degraded via proteolysis. It is a sterile, preservative-free, white-to-off-white lyophilized powder for IV infusions. It improved ptosis, diplopia, CAS score, and quality of life in patients with moderate-to-severe Graves\u2019 ophthalmopathy and had a favorable safety profile. <\/p>\n\n\n\n<p>Tepezza has become a go-to <a href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-market\">treatment for moderate to severe thyroid eye disease<\/a>, with unseating orbital decompression as the most used Graves\u2019 ophthalmopathy treatment. TEPEZZA witnessed a YoY growth of <strong>103%<\/strong> within the 1st year of launch. As per DelveInsight Estimates, the drug will continue to grow at a <strong>CAGR of ~10%<\/strong> owing to its launch in EX-US geographies and label expansion to include chronic Graves\u2019 ophthalmopathy patients. It is currently being studied in Japan as part of a Phase III (jRCT2031210453) trial to treat active Graves\u2019 ophthalmopathy in Japanese patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Competitors_in_Pipeline_for_Graves_Ophthalmopathy_Treatment\"><\/span><strong>Key Competitors in Pipeline for Graves\u2019 Ophthalmopathy Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Graves\u2019 ophthalmopathy arena is finally beginning to evolve. <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-pipeline-insight\">New Graves\u2019 ophthalmopathy drugs<\/a> with the potential to provide sustained benefits are expected to contribute to the exponential Graves\u2019 ophthalmopathy treatment market growth. The drug candidates by key players, such as <strong>Immunovant Sciences (batoclimab), Novartis Pharmaceuticals (secukinumab), Viridian Therapeutics (VRDN-001), Sling Therapeutics (linsitinib), Regeneron Pharmaceuticals (aflibercept), ValenzaBio (VB421)<\/strong>, and others under late- and mid-phase clinical development have the potential to create a significant positive shift in Graves\u2019 ophthalmopathy market size. The launch of emerging therapies for Graves\u2019 ophthalmopathy treatment is expected during the forecast period of 2023\u20132032.<\/p>\n\n\n\n<p><strong>Batoclimab (Immunovant Sciences) <\/strong>is being studied for the treatment of severe autoimmune diseases caused by pathogenic immunoglobulin G (IgG), such as Graves\u2019 ophthalmopathy. It was evaluated in an open-label, single-arm Phase IIa <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-pipeline-insight\">clinical trial for Graves\u2019 ophthalmopathy treatment<\/a> in 2019. The majority of participants (four of seven) tested at the end of treatment improved their clinical activity score (CAS) by two points. Three of the seven participants were IMVT-1401 proptosis responders. Later, the company achieved FDA alignment, and a Phase IIb trial was initiated and halted in February 2021 due to elevated total cholesterol and low-density lipoprotein levels observed in some trial subjects treated DA Division of Ophthalmology to move forward in Graves\u2019 ophthalmopathy and initiated two Phase III (NCT05524571, NCT05517421) clinical trials to evaluate batoclimab to treat Graves\u2019 ophthalmopathy Top-line findings from both Phase III trials are expected in the first half of 2025.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091912\/Promising-Therapies-for-Graves-Ophthalmopathy-1024x242.png\" alt=\"Promising Therapies for Graves\u2019 Ophthalmopathy\" class=\"wp-image-22787\" width=\"768\" height=\"182\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091912\/Promising-Therapies-for-Graves-Ophthalmopathy-1024x242.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091912\/Promising-Therapies-for-Graves-Ophthalmopathy-300x71.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091912\/Promising-Therapies-for-Graves-Ophthalmopathy-150x35.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091912\/Promising-Therapies-for-Graves-Ophthalmopathy-768x181.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19091912\/Promising-Therapies-for-Graves-Ophthalmopathy.png 1191w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/figure>\n\n\n\n<p><strong>COSENTYX (secukinumab) <\/strong>developed by<strong> Novartis<\/strong> is an immunosuppressant agent. It is manufactured as a freeze-dried powder solution and solution in a prefilled syringe or pen for SC delivery. It is a completely human monoclonal anti-IL-17A recombinant antibody that is now licensed for the treatment of three inflammatory\/autoimmune diseases: moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The drug is currently being studied in a Phase III (NCT04737330) trial to determine the efficacy and safety of secukinumab in adult patients with active, moderate-to-severe thyroid eye disease.<\/p>\n\n\n\n<p><strong>VRDN-001, Viridian\u2019s<\/strong> lead product candidate, is a differentiated monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially recognized target for the treatment of Graves\u2019 disease. The medicine is currently being tested in a Phase II\/III (NCT05176639) trial to determine its safety, tolerability, and efficacy in active Graves\u2019 ophthalmopathy patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Graves_Ophthalmopathy_Treatment_Looks_Promising\"><\/span><strong>Future Graves\u2019 Ophthalmopathy Treatment Looks Promising&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Graves\u2019 ophthalmopathy treatment market is expected to see multiple approvals in the near future. DelveInsight estimates that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-market\">Graves\u2019 ophthalmopathy market<\/a> is expected to grow from approximately USD 2 billion in 2022 at a significant ~15% CAGR by 2032. As per the estimates <strong>~98%<\/strong> of this revenue is attributed to the sales of <strong>TEPEZZA <\/strong>in the US.&nbsp;<\/p>\n\n\n\n<p>In addition, recent attempts to raise patient and clinician awareness of Graves\u2019 ophthalmopathy through various awareness programs are expected to result in earlier diagnosis and Graves\u2019 ophthalmopathy treatment. Furthermore, the first step in ocular drug discovery programs is to design an effective molecule with an intended delivery strategy matched to the target compartment. <\/p>\n\n\n\n<p>Moreover, the lack of disease-modifying therapeutic options for <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-epidemiology-forecast\">chronic Graves\u2019 ophthalmopathy patients<\/a> substantially influences their mental and social well-being. As a result, the dynamics of the Graves\u2019 ophthalmopathy treatment market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending worldwide.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-ophthalmopathy-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-1024x256.png\" alt=\"Graves\u2019 Ophthalmopathy Therapeutics Market Assessment\" class=\"wp-image-22803\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150805\/Graves-Ophthalmopathy-Therapeutics-Market-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1684467627608\"><strong class=\"schema-faq-question\"><strong>1. What is Graves\u2019 ophthalmopathy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Graves\u2019 ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most common extrathyroidal manifestation of Graves\u2019 disease. It is an autoimmune disease in which the generation of autoantibodies causes inflammatory changes in the orbit. The autoantibodies are thought to be directed at a protein that is found in both the orbit and the thyroid.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1684467644822\"><strong class=\"schema-faq-question\"><strong>2. What are Graves\u2019 ophthalmopathy symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Graves\u2019 ophthalmopathy symptoms include eye irritation or grittiness, redness or inflammation of the conjunctiva, excessive tears or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1684467674172\"><strong class=\"schema-faq-question\"><strong>3. How is Graves\u2019 ophthalmopathy diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">The doctor may suggest scans, such as a computerized tomography (CT) scan or an MRI, to discover changes in the muscles around the eyes for Graves\u2019 ophthalmopathy diagnosis. They may also need blood testing to see whether their thyroid hormone levels and antibodies are too high or too low.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1684467689323\"><strong class=\"schema-faq-question\"><strong>4. What are the current Graves\u2019 ophthalmopathy treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">The Graves\u2019 ophthalmopathy treatment is determined by the patient\u2019s symptoms and severity and includes basic, medicinal, and surgical treatments. The optimal Graves\u2019 ophthalmopathy treatment goal is to reduce the risk of visual difficulties, minimize adverse effects, eliminate the need for surgical treatments, restore thyroid function, and prevent Graves\u2019 ophthalmopathy from progressing or recurring.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Graves\u2019 ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most frequent extrathyroidal manifestation of Graves\u2019 disease. The majority of Graves\u2019 ophthalmopathy cases are caused due to Graves\u2019 disease, and only a small percentage of these patients arise from other euthyroid or hypothyroid disorders.&nbsp; As per DelveInsight\u2019s estimates, as of 2022, ~2.4 [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":22798,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":6,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[7778,20703,20702,20704,20701,17971,7777],"industry":[17225],"therapeutic_areas":[17244],"class_list":["post-22783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-graves-ophthalmopathy","tag-graves-ophthalmopathy-drugs","tag-graves-ophthalmopathy-market","tag-graves-ophthalmopathy-patients","tag-graves-ophthalmopathy-treatment","tag-tepezza","tag-thyroid-eye-disease","industry-pharmaceutical","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evolving Landscape of Graves\u2019 Ophthalmopathy Treatment Market<\/title>\n<meta name=\"description\" content=\"Graves\u2019 ophthalmopathy treatment market expected to change due to raising awareness, R&amp;D activities, and multiple approvals in near future.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evolving Landscape of Graves\u2019 Ophthalmopathy Treatment Market\" \/>\n<meta property=\"og:description\" content=\"Graves\u2019 ophthalmopathy treatment market expected to change due to raising awareness, R&amp;D activities, and multiple approvals in near future.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-19T09:35:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-24T04:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150333\/Graves-Ophthalmopathy-Therapeutics-Assessment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evolving Landscape of Graves\u2019 Ophthalmopathy Treatment Market","description":"Graves\u2019 ophthalmopathy treatment market expected to change due to raising awareness, R&D activities, and multiple approvals in near future.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment","og_locale":"en_US","og_type":"article","og_title":"Evolving Landscape of Graves\u2019 Ophthalmopathy Treatment Market","og_description":"Graves\u2019 ophthalmopathy treatment market expected to change due to raising awareness, R&D activities, and multiple approvals in near future.","og_url":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-05-19T09:35:38+00:00","article_modified_time":"2023-05-24T04:02:11+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150333\/Graves-Ophthalmopathy-Therapeutics-Assessment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment","url":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment","name":"Evolving Landscape of Graves\u2019 Ophthalmopathy Treatment Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150333\/Graves-Ophthalmopathy-Therapeutics-Assessment.png","datePublished":"2023-05-19T09:35:38+00:00","dateModified":"2023-05-24T04:02:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Graves\u2019 ophthalmopathy treatment market expected to change due to raising awareness, R&D activities, and multiple approvals in near future.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467627608"},{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467644822"},{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467674172"},{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467689323"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150333\/Graves-Ophthalmopathy-Therapeutics-Assessment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150333\/Graves-Ophthalmopathy-Therapeutics-Assessment.png","width":772,"height":482,"caption":"Graves\u2019 Ophthalmopathy Therapeutics Assessment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467627608","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467627608","name":"1. What is Graves\u2019 ophthalmopathy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Graves\u2019 ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most common extrathyroidal manifestation of Graves\u2019 disease. It is an autoimmune disease in which the generation of autoantibodies causes inflammatory changes in the orbit. The autoantibodies are thought to be directed at a protein that is found in both the orbit and the thyroid.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467644822","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467644822","name":"2. What are Graves\u2019 ophthalmopathy symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Graves\u2019 ophthalmopathy symptoms include eye irritation or grittiness, redness or inflammation of the conjunctiva, excessive tears or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467674172","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467674172","name":"3. How is Graves\u2019 ophthalmopathy diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The doctor may suggest scans, such as a computerized tomography (CT) scan or an MRI, to discover changes in the muscles around the eyes for Graves\u2019 ophthalmopathy diagnosis. They may also need blood testing to see whether their thyroid hormone levels and antibodies are too high or too low.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467689323","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment#faq-question-1684467689323","name":"4. What are the current Graves\u2019 ophthalmopathy treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The Graves\u2019 ophthalmopathy treatment is determined by the patient\u2019s symptoms and severity and includes basic, medicinal, and surgical treatments. The optimal Graves\u2019 ophthalmopathy treatment goal is to reduce the risk of visual difficulties, minimize adverse effects, eliminate the need for surgical treatments, restore thyroid function, and prevent Graves\u2019 ophthalmopathy from progressing or recurring.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/19150333\/Graves-Ophthalmopathy-Therapeutics-Assessment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 ophthalmopathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 ophthalmopathy drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 Ophthalmopathy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 ophthalmopathy patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 Ophthalmopathy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tepezza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Thyroid eye disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Graves\u2019 ophthalmopathy<\/span>","<span class=\"advgb-post-tax-term\">Graves\u2019 ophthalmopathy drugs<\/span>","<span class=\"advgb-post-tax-term\">Graves\u2019 Ophthalmopathy Market<\/span>","<span class=\"advgb-post-tax-term\">Graves\u2019 ophthalmopathy patients<\/span>","<span class=\"advgb-post-tax-term\">Graves\u2019 Ophthalmopathy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Tepezza<\/span>","<span class=\"advgb-post-tax-term\">Thyroid eye disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 19, 2023","modified":"Updated on May 24, 2023"},"absolute_dates_time":{"created":"Posted on May 19, 2023 3:05 pm","modified":"Updated on May 24, 2023 9:32 am"},"featured_img_caption":"Graves\u2019 Ophthalmopathy Therapeutics Assessment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=22783"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22783\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/22798"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=22783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=22783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=22783"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=22783"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=22783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}